Bayer's cell therapy unit BlueRock Therapeutics lays off about 50 employees
BlueRock Therapeutics, the cell therapy arm of German pharma giant Bayer, let go of about 50 employees on Tuesday as the biotech focuses on bringing its Parkinson’s disease cell therapy into Phase II and moving another cell therapy into the clinic in the near-term.
The biotech, which Bayer fully bought out in 2019, said earlier this summer it plans to move its lead cell therapy bemdaneprocel (or BRT-DA01) into a Phase II in the first half of next year after saying it was safe in a Phase I.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.